Post-Combination Sequencing and Resistance Mechanisms

Dr. Somaiah addresses the critical question of treatment sequencing after combination second-line therapy, acknowledging that all currently approved agents were studied as sequential monotherapies without prospective data on their performance following combination treatment. This represents uncharted territory requiring clinical experience and real-world data collection.

Ripretinib's switch-control mechanism provides mechanistic rationale for retained activity after combination therapy, as its mutation coverage is based on binding characteristics rather than prior regimen exposure. The drug's ability to target both switch pocket and activation loop sites should theoretically remain intact regardless of previous treatment combinations.

Future resistance mechanisms after combination therapy remain unknown, though the panel discussed emerging "APAL" mutations (primary plus ATP-binding pocket plus activation loop) that represent triple mutations potentially resistant to all current agents. Understanding whether combination therapy delays, prevents, or alternatively accelerates such complex resistance patterns will be crucial for optimizing treatment sequences.

Near-term sequencing decisions will likely rely on clinical experience, institutional protocols, and real-world evidence rather than prospective trial data. The importance of collecting ctDNA at progression and participating in clinical trials cannot be overstated for advancing the field's understanding of optimal sequencing strategies.

Dr. Heinrich emphasizes that using the most effective therapy early may prevent complex resistance emergence, though this remains theoretical pending long-term follow-up data. The goal involves maximizing initial disease control while preserving subsequent treatment options, requiring careful balance between aggressive early intervention and sequential treatment preservation.